Daewoong to export gastric acid blocker to Mexico - (The Korea Herald via NewsPoints Desk)

  • Daewoong Pharmaceutical said Wednesday it reached a deal worth $50 million to supply fexuprazan to Mexico's Moksha8, which aims to launch the gastric acid blocker in the second half of 2022, reported The Korea Herald.

  • According to the news source, the expansion of Daewoong's fexuprazan to overseas markets is in direct competition with CJ HealthCare's tegoprazan-based K-CAB.

  • Both fexuprazan and tegoprazan are potassium-competitive acid blockers, an advanced treatment compared to proton-pump inhibitors, which make up 95% of antiulcer drugs in Mexico, the news source noted.

  • K-CAB is marketed locally by Laboratorios Carnot and is expected to launch in 2021.

  • Meanwhile, Daewoong is preparing to start clinical trials of fexuprazan in the US and China.

To read more NewsPoints articles, click here.

Reference Articles